SCHEMBL5886575

SCHEMBL5886575

CCCCC#Cc1ccco1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 11/20 0.43
ADORA2A P29274 10/20 0.43
ADORA1 P30542 7/20 0.43
ADORA2B P29275 6/20 0.43
KCNH2 Q12809 1/20 0.41
POLB P06746 2/20 0.39
RECQL P46063 1/20 0.39
ALOX5 P09917 1/20 0.36
MAPT P10636 3/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
APEX1 P27695 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886617 0.93 KCNH2 (0.50) ADORA3ADORA2AADORA1ADORA2BKCNH2
SCHEMBL13626441 0.89 ALOX5 (0.37) ADORA3ADORA2AADORA1ADORA2BKCNH2
Potassium SCHEMBL2593640 0.80 KCNH2 (0.42) ADORA3ADORA2AADORA1ADORA2BKCNH2
SCHEMBL9906388 0.80
SCHEMBL6643512 0.77 ALOX5 (0.37) ALOX5MAPTKDM4ECYP1A2CYP3A4
SCHEMBL16347674 0.75 MAPT (0.32) ADORA3ADORA2AADORA1ADORA2BALOX5
SCHEMBL8863670 0.74 PTPN7 (0.44) POLBRECQLALOX5MAPTKDM4E
SCHEMBL16345143 0.72
SCHEMBL16345466 0.72
SCHEMBL7571198 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105707-B2 Process for preparing alkynyl-substituted aromatic and heterocyclic compounds PHARMACORE, INC. (US) 2006-09-12 US disclosed
US-20050137402-A1 Process for preparing alkynyl-substituted aromatic and heterocyclic compounds DSM N.V. (NL) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137402-A1 Process for preparing alkynyl-substituted aromatic and heterocyclic compounds NAT1, B3GNT2, NISCH ADORA3 3425/4885ADORA2A 2801/4885ADORA1 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.